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A Note From NIDA’s Director
T
he scientific research funded and conducted by
NIDA produces profound insights into the work-
ings of the brain and the dynamic interactions
between people, their environments, and substances.
Many of these insights have significance well beyond the
field of drug abuse, and some of them provide scien-
tists with a sense of beauty that would be well worth
pursuing for its own sake. However, we have not accom-
plished our institutional goal until we find ways to use our
discoveries to reduce the prevalence and consequences
of drug abuse and addiction.
Our challenge is to create links between the produc-
tion of scientific knowledge and its application. Science &
Practice Perspectives, fostering dialogue between clinicians
and researchers, is one such link. Another is our Clinical
Trials Network (CTN), in which university research cen-
ters and community clinics jointly design and conduct
studies on important topics related to treatment. 
NIDA’s annual conferences titled “Blending Clinical
Practice and Research” are yet another mechanism to
unite research and practice. Three past meetings have
each drawn hundreds of scientists, clinicians, and poli-
cymakers to an intensive program of presentations and
workshops addressing a broad range of clinical, admin-
istrative, and strategic issues. Participants received advance
orientation concerning important breaking developments
in the field, for example, in sessions on buprenorphine.
To view a selection of some 50 session titles and visuals
from those meetings, readers can go to www.drugabuse.gov/
whatsnew/meetings/blending2002/presentation.html.
This year’s Blending conference, co-hosted by Wayne
State University and the CTN Great Lakes Node, takes
place in Detroit on September 27 and 28. Program high-
lights and information about registration will be posted
soon on NIDA’s Web site (www.drugabuse.gov). If you find
Science & Practice Perspectives interesting and useful, this
meeting could be for you.
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